Inmode (INMD)
NASDAQ:INMD
Want to see INMD full AI Analyst Report?
INMD Stock Chart & Stats
$14.65
-$1.18(-6.78%)
At close: 4:00 PM EST
$14.65
-$1.18(-6.78%)
Day’s Range― - ―
52-Week Range$12.72 - $16.74
Previous CloseN/A
Volume968.14K
Average Volume (3M)888.39K
Market Cap
$857.88M
Enterprise Value$493.12M
Total Cash (Recent Filing)$537.16M
Total Debt (Recent Filing)$4.83M
Price to Earnings (P/E)9.8
Beta0.97
Next Earnings
Jul 23, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.38
Shares Outstanding63,358,750
10 Day Avg. Volume1,039,725
30 Day Avg. Volume888,388
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.39
Price to Sales (P/S)2.56
P/FCF Ratio11.26
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda5.00
Forecast
1Y Price Target
$15.75Price Target Upside7.51% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)1.34
Revenue Forecast (FY)$370.03M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a large equity/cash base provide durable financial flexibility. This supports capital returns, R&D or opportunistic M&A, and lets the company weather cyclical demand in aesthetics without forcing distressed asset sales or emergency financing.
High-Quality Cash GenerationNear one-to-one conversion of net income to free cash flow indicates cash quality and repeatable internal funding. Reliable cash generation underpins buybacks, reinvestment in product development, and service/support for the installed base, strengthening long-term resilience.
Product Platform & Installed-Base MomentumBroadening platform portfolio and pipeline FDA filings expand addressable procedures and drive capital sales. A growing installed base from diversified devices supports recurring consumable and service revenue, improving revenue durability even if device sales cycle.
Bears Say
Multi-year Revenue SlowdownSustained revenue declines over multiple years weaken installed-base growth and slow future consumable pull-through. A smaller growth runway limits operating leverage and makes sustained margin recovery harder without material market or product-driven demand improvement.
Margin CompressionMaterial compression in gross and operating margins reduces cashflow available for reinvestment and returns. If newer platforms or higher product mix/discounting continue to erode margins, the company's high-profitability structural advantage may be harder to sustain long term.
Leadership & Governance TurnoverSenior finance and board turnover during a reorganization and recovery phase raises execution risk on cost controls, guidance delivery, and capital allocation. Combined with prior failed sale attempts and a securities class action, governance disruptions could slow strategic initiatives.
InMode News
INMD FAQ
What was Inmode’s price range in the past 12 months?
Inmode lowest stock price was $12.72 and its highest was $16.74 in the past 12 months.
What is Inmode’s market cap?
Inmode’s market cap is $857.88M.
When is Inmode’s upcoming earnings report date?
Inmode’s upcoming earnings report date is Jul 23, 2026 which is in 46 days.
How were Inmode’s earnings last quarter?
Inmode released its earnings results on May 06, 2026. The company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.298 by -$0.048.
Is Inmode overvalued?
According to Wall Street analysts Inmode’s price is currently Undervalued.
Does Inmode pay dividends?
Inmode does not currently pay dividends.
What is Inmode’s EPS estimate?
Inmode’s EPS estimate is 0.33.
How many shares outstanding does Inmode have?
Inmode has 63,358,750 shares outstanding.
What happened to Inmode’s price movement after its last earnings report?
Inmode reported an EPS of $0.25 in its last earnings report, missing expectations of $0.298. Following the earnings report the stock price went down -5.625%.
Which hedge fund is a major shareholder of Inmode?
Currently, no hedge funds are holding shares in INMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InMode Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.75 (7.51% Upside)
$15.75 (7.51% Upside)
Blogger Sentiment
Bullish
INMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 239.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.57%
12-Months-Change
Fundamentals
Return on Equity
13.28%
Trailing 12-Months
Asset Growth
6.54%
Trailing 12-Months
Company Description
Inmode
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
INMD Company Deck
INMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call contained a mix of modest top-line progress and strategic positives (5% revenue growth, strong cash balance, product launches, sales reorganization and share repurchases) offset by notable margin compression, rising operating expenses and declines in EPS. Management provided steady full-year guidance and described early signs of stabilization in the U.S., but profitability pressures and macroeconomic headwinds temper the outlook. International and product development initiatives offer upside, while near-term margin and demand uncertainty are the primary negatives.View all INMD earnings summariesINMD Stock 12 Month Forecast
Average Price Target
$15.75
▲(7.51% Upside)
Technical Analysis
Orthofix Medical
―
AxoGen
―
Establishment Labs Holdings
―
SS Innovations International
―
Bioventus
―
Ownership Overview
―
Insiders
5.94% Mutual Funds
24.43% Other Institutional Investors
66.10% Public Companies and Individual Investors